Analysis of Clinical Benefit Using DNG64-CAR-V Chimeric Tumor Targeted Amphotropic RNA Vector in CCNG1 Expressing Cancers

Artistic Illustration of DNG64-CAR-V. The DNG64 chimeric amphotropic RNA vector [CAR-V] displaying a SIG targeting peptide (A-C), for binding to abnormally exposed Signature [SIG] proteins in the tumor microenvironment (TME) (B), and encoding a cytocidal dominant negative human cyclin G1 inhibitor gene (C). Injected intravenously, DNG64-CAR-V nanoparticles find and bind to abnormal SIG proteins exposed in the TME, which augments effective vector concentration in tumors. DNG64-CAR-V kills not only cancer cells and tumor associated vasculature, but also kills cancer associated fibroblasts and reduces stroma production which facilitates entry of immune cells, cancer drugs and immune checkpoint inhibitors into the TME (adapted from Chawla 2019).